Source comparison
Tesamorelin + Ipamorelin Blend News 2026: Dosing Comparison
The tesamorelin + ipamorelin blend news 2026 includes clarification on dosing variability across published protocols, which has historically caused confusion when researchers attempt to replicate results. The table below compares the three major 2026 protocols
This comparison does not assign a generated winner or score.
- The tesamorelin + ipamorelin blend news 2026 includes clarification on dosing variability across published protocols, which has historically caused confusion when researchers attempt to replicate results. The table below compares the three major 2026 protocols discussed in peer-reviewed publications.
- Miami Metabolic Research Institute
- 2mg daily
- 200mcg
- 3× daily (AM, midday, PM)
- Visceral adipose tissue (DEXA)
- 18.3%
- 41 ng/mL
- Scripps Translational Science Institute
- 1mg daily
- 300mcg
- 2× daily (AM, PM)
- IGF-1 serum levels
- 14.7%
- 47 ng/mL
- Canadian Centre for Peptide Therapeutics
- Metabolic safety (HbA1c, fasting glucose)
- 17.9%
- 39 ng/mL
- Tesamorelin Monotherapy (control)
- None
- 1× daily (PM)
- 13.4%
- 29 ng/mL
- Ipamorelin Monotherapy (control)
- 7.9%
- 8 ng/mL
- The Miami and Canadian protocols produced near-identical VAT reduction results despite identical dosing, which supports reproducibility. The Scripps protocol, using lower tesamorelin dose but higher ipamorelin dose, achieved the highest IGF-1 elevation but slightly lower VAT reduction. Consistent with the hypothesis that sustained GHRH receptor activation (via higher-dose tesamorelin) drives more pronounced lipolytic signalling in visceral adipocytes. All three studies used subcutaneous injection, reconstitution with bacteriostatic water at 2mL total volume per vial, and storage at 2–8°C post-reconstitution.